FDA Emergency Authorization: IgG/IgM Rapid Coronavirus Diagnostic


The test uses whole blood, plasma, or serum. The testing kit is intended to produce reliable results within 10 minutes.

Premier Biotech released a statement revealing that the US Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) to its SARS-CoV-2 IgG and IgM rapid diagnostic.

The test uses whole blood, plasma, or serum. The testing kit is intended to produce reliable results within 10 minutes.

"The FDA's decision to grant Biotest's product EUA is great news for communities across the U.S. that continue to struggle to access adequate COVID-19 testing, which healthcare experts agree is essential to successful recovery from the COVID-19 crisis," said Premier Biotech CEO Todd Bailey in the announcement release.

False negatives and variable reliability plagued earlier tests across the diagnostics industry, but Premier claimed that the test met rigorous testing standards. Premier Biotech attracted the skepticism of a U.S. House subcommittee over concerns its tests are not as accurate as presented.

Premier has defended its previous tests, and intends to release more information on accuracy as it emerges.

"As the grant of EUA confirms, the National Cancer Institute has verified this product exceeds the 95% specificity and 90% sensitivity standards set by the FDA. Undoubtedly, this product is in clear alignment with Premier Biotech's rigorous compliance standards and commitment to distributing high-quality testing solutions. We will continue to follow the regulatory guidelines closely as we distribute the product for emergency use to authorized laboratories nationwide.”

Related Stories:

  • Dealing With False Negatives

The authors of a new commentary published in Mayo Clinic Proceedings explained that while positive results from certain tests can be very helpful, negative COVID-19 diagnostic results may lead to a false sense of security.

  • FDA Expands COVID-19 At-Home Test Collection Authorization to Saliva Samples

The US Food and Drug Administration expanded the existing Emergency Use Authorization (EUA) for the Rutgers Clinical Genomics Laboratory to now include the at-home collection of saliva samples for COVID-19 testing.

The extension of the EUA, originally granted last week, indicates the Spectrum Solutions SDNA-1000 saliva collection can be used for self-collection at home. This is the first and currently only FDA authorization of at-home saliva collection for physician-prescribed COVID-19 testing.

  • Recap: 5 COVID-19 Related FDA Authorizations in May 2020

A review of 5 COVID-19 related FDA authorizations from the first 10 days of May.

(Interview) Rodney E. Rhode, PhD: Do We Have Enough Trained Laboratory Specialists for Mass Coronavirus Testing?

Segment Description: Rodney E. Rohde, PhD, Chair & Professor of the Clinical Laboratory Science Program at Texas State University discusses the challenges our shortage of medical laboratory specialists creates for the COVID-19 response. Dr. Rohde also describes the unique careers available to medical lab specialists alongside the reasons few medical students are aware of the profession.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.